Enjoy. But please read the entire article before you go online, buy a GLP-1 and start injecting yourself.
The Anti-Aging Drug We Keep Calling a Weight-Loss Shot
pharmaceutical
GLP-1 Just $50 a Month!!!
Starting July 1, 2026 Medicare covers certain GLP-1 drugs under the Medicare GLP-1 Bridge program. This temporary program is available nationwide (including all states and U.S. territories) to certain people with Medicare drug coverage (Part D). https://www.medicare.gov/coverage/weight-loss-drugs
You must be 18 or older and meet one of these requirements when you start GLP-1 therapy:
You have a body mass index (BMI) of 35 or more.
You have a BMI between 30-34.99 and have at least one of these conditions:
Diastolic heart failure (also called heart failure with preserved ejection fraction)
Uncontrolled high blood pressure (also called hypertension)
Chronic kidney disease at stage 3a or higher
Prediabetes
A previous heart attack (also called myocardial infarction) or stroke
Blocked arteries in your legs or arms (also called peripheral artery disease) with symptoms
You have a BMI between 27-29.99 and have at least one of these conditions:
Prediabetes
A previous heart attack (also called myocardial infarction) or stroke
Blocked arteries in your legs or arms (also called peripheral artery disease) with symptoms
Yes, I loved writing the click bait title to this post.
The Dangers of Self-Diagnosis and AUD (Alcohol Use Disorder)
Using naltrexone to cut back on drinking isn’t new, says Sarah Wakeman, a senior medical director for substance use disorder at Mass General Brigham. The approach dates back to the 1980s with the Sinclair method, which pairs drinking with naltrexone to blunt alcohol’s pleasurable effects. In parts of Europe, Wakeman adds, people have long used a “pill-in-the-pocket” strategy, taking the medication only when they anticipate drinking. A decades-old drug is helping people drink less alcohol—without giving it up completely – https://www.nationalgeographic.com/health/article/naltrexone-drink-less-alcohol? (Paywall article)
The Provider Individual who is not a doctor will see you after you answer the questionnaire (this is the self-diagnosis part).
Oar Health is an online service offering naltrexone subscriptions to those with alcohol use disorder (AUD). Users can fill out a brief assessment which is reviewed by a medical professional, then be given a naltrexone prescription if appropriate. After a one-time $50 fee, subscriptions cost $297 for three months of medication, which comes out to $99 monthly. It’s currently available in 42 US states. Beyond the naltrexone prescription, Oar Health offers ongoing access to the support of a medication prescriber, a health coach, a Facebook group for community support, and extras like educational articles and guided reflections.Oar Health Review: Pros & Cons, Cost, & My Experience – https://www.choosingtherapy.com/oar-health-review/
Health coaches who are “naltrexone experts”! And The Sinclair Method might not work for everyone. https://drugfree.org/article/sinclair-method/
Depending upon the online service you choose you may get naltrexone prescribed when trying to get your doctor prescribed GLP-1 filled out even when you don’t have alcohol use disorder.
Telehealth companies such as Vida Health and its rivals offer lifestyle support so people taking drugs like Wegovy and Zepbound can have the most success on the drugs. But the companies often have another job: limiting obesity drug costs for employers.
The Vida Health nurse said he was a good candidate for Zepbound but insisted he try two generic drugs first: naltrexone, a drug used to curb alcohol and opioid use, and bupropion, an antidepressant. Neither drug is approved for obstructive sleep apnea. Primary care doctors raise alarm as telehealth companies get involved in obesity drugs – https://www.npr.org/2026/06/14/nx-s1-5805984/glp1-telehealth-weight-loss-drugs
Yikes.
Medscape on Obesity – 04.26.26
GLP-1s (it’s kind of a mess)
“But the real question is what is the quality of the weight regain and what is the shift in people’s metabolism, and it seems to be very bad,” she said. “Ongoing studies that haven’t been published yet suggest that hypertension comes back. All the inflammatory markers come back, and lipids go up. And if you have diabetes, it gets worse. Overall, it’s kind of a mess…As these studies and others showed, most people regain the weight. Whether or not they regain all the weight depends in part on diabetes and insulin and many other factors, but people will likely regain most of their weight.”
“But the message isn’t that you regain the weight. The message is that you may be less healthy when you regain the weight. That’s why we need to couple the drugs with lifestyle interventions. And it’s why people who just want to lose 5 or 10 pounds really need to consider that lifestyle change, hard as it is, is the better way to do it.”
Anne Peters, MD, professor Keck School of Medicine of the University of Southern California
Less Weight Regain, More Health Loss after Stopping GLP-1s? – Medscape – March 05, 2026 – https://www.medscape.com/viewarticle/less-weight-regain-more-health-loss-after-stopping-glp-1s-2026a10006rv?
I never envisioned developing an obsession with pharmaceuticals. And after many years of endless blogging into the void I learned I could link to previous posts like this: https://lifeunderwriter.net/tag/glp-1-receptor-agonist/
The learning never stops.
Medscape on Obesity – 02.08.26
Scary Charts 01.30.26
Weight-loss drugs draw thousands of lawsuits alleging serious harm – https://www.usatoday.com/story/news/nation/2026/01/28/glp-1-weight-loss-drug-lawsuits-side-effects/87611067007/
Yikes.
GLP-1s and the Risk for Malnutrition
“We see cases where people take a GLP-1 medication and become so severely malnourished that they need to be hospitalized,” said Rebecca Boswell, PhD, director of Penn Medicine Princeton Center for Eating Disorders, in Philadelphia. “It’s not uncommon.” The Scary Health Risk That Can Sneak Up on GLP-1 Users – Medscape – January 19, 2026. https://www.medscape.com/viewarticle/scary-health-risk-can-sneak-glp-1-users-2026a10001pi
Yikes.
People return to their baseline weight and lose all cardiometabolic benefits in less than 2 years after stopping semaglutide or tirzepatide, a new meta-analysis found. Weight Regain, Health Benefit Loss Rapid When GLP-1s Stopped – Medscape – January 08, 2026. https://www.medscape.com/viewarticle/weight-regain-health-benefit-loss-rapid-when-glp-1s-stopped-2026a10000kr?
YIKES.
You see, cures are passée. Cures kill markets. Getting the population properly hooked on a pharmaceutical treatment for a ‘chronic’ condition is where the serious money is. “Our core insight was simple and grim: it’s far easier—and infinitely more profitable—to convince healthy people that they’re sick than to develop genuine cures for the truly ill.“
Twenty years later, the hustle is bigger, slicker, and more dangerous than ever. Watching that hustle unfold with weight loss drugs feels weirdly ominous, like watching a slow-moving train wreck you can’t peel your eyes off of. You know there’ll be carnage and bodies, vast fortunes won and lost, and humanity left just a little bit poorer. We have often documented the pharmaceutical industry’s proven ability to create enormously lucrative markets overnight, by inventing and selling diseases. Now watch as all that ingenuity and energy gets pointed at one of the biggest problems bewitching humanity: human fatness. The Seven Deadly Sins of Weight Loss Drugs – https://brownstone.org/articles/the-seven-deadly-sins-of-weight-loss-drugs/
YIKES!
This will not end well.
Complications? What Complications? (just another GLP-1 receptor agonist post)
My Statin Comes From India
According to the USP, the bulk of the APIs come from India. That country is responsible for 50% of the active pharmaceutic ingredients. China is not far behind at 32%. The European Union supplies 10%. That’s a big change since 2000. Back then, European countries like France, Germany, Switzerland and Denmark supplied 42% of the APIs. Drug Recalls From India – Can You Trust Foreign-Made Generics? – https://www.peoplespharmacy.com/articles/more-drug-recalls-from-india-do-you-trust-foreign-made-generics
Dozens of companies received approval from the FDA over the years to sell metoprolol and bupropion in the U.S. Yet from 2018 to 2024, the agency reported running only 2 tests on metoprolol and 7 on bupropion through its quality surveillance program — in each case, by pulling a sample from a single drug maker. In many of those years, the drugs weren’t tested at all, FDA records show. Those that were assessed received passing results. The FDA Often Doesn’t Test Generic Drugs for Quality Concerns, So ProPublica Did – https://www.propublica.org/article/fda-generic-drug-testing
ClinCalc DrugStats Database – https://clincalc.com/DrugStats/
Both articles are long reads but worth your time.
Yikes.
Antidepressant Prescriptions Increase 130% for Teenage Girls
The increasing rate of mental health disorders among children and adolescents is a concerning trend that has been observed for several decades, with survey studies revealing dramatic increases in anxiety, depression, and suicidal ideation.1 In the United States, suicide ranks as the second leading cause of death for those aged 10 to 19 years and the third leading cause of death for those aged 15 to 24 years.2 Antidepressant Prescriptions and Mental Health – https://publications.aap.org/pediatrics/article/153/3/e2023064677/196661/Antidepressant-Prescriptions-and-Mental-Health
Between January 2016 and December 2022, the monthly antidepressant dispensing rate increased 66.3%, from 2575.9 to 4284.8. Before March 2020, this rate increased by 17.0 per month (95% confidence interval: 15.2 to 18.8). The COVID-19 outbreak was not associated with a level change but was associated with a slope increase of 10.8 per month (95% confidence interval: 4.9 to 16.7). The monthly antidepressant dispensing rate increased 63.5% faster from March 2020 onwards compared with beforehand. In subgroup analyses, this rate increased 129.6% and 56.5% faster from March 2020 onwards compared with beforehand among females aged 12 to 17 years and 18 to 25 years, respectively. In contrast, the outbreak was associated with a level decrease among males aged 12 to 17 years and was not associated with a level or slope change among males aged 18 to 25 years. Antidepressant Dispensing to US Adolescents and Young Adults: 2016–2022 – https://publications.aap.org/pediatrics/article/153/3/e2023064245/196655/Antidepressant-Dispensing-to-US-Adolescents-and?autologincheck=redirected
Between 2020 and 2022, antidepressant prescriptions for girls aged 12-17 skyrocketed by 130%. Antidepressants Increase 130% for Teen Girls, Drop 7% For Boys – https://brownstone.org/articles/antidepressants-increase-130-for-teen-girls-drop-7-for-boys/
Yikes.
lifeunderwriter.net 
You must be logged in to post a comment.